Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average rating of “Buy” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the last year is $6.60.

TSHA has been the subject of a number of recent research reports. Jefferies Financial Group reissued a “buy” rating and set a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Piper Sandler decreased their price target on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, July 1st. BMO Capital Markets began coverage on shares of Taysha Gene Therapies in a report on Thursday, June 27th. They set an “outperform” rating and a $5.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Finally, Needham & Company LLC reissued a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, July 23rd.

Taysha Gene Therapies Stock Down 2.8 %

Shares of NASDAQ:TSHA opened at $2.10 on Monday. The stock’s 50 day moving average is $2.77 and its 200-day moving average is $2.53. Taysha Gene Therapies has a twelve month low of $0.66 and a twelve month high of $4.32. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the prior year, the company posted ($0.28) earnings per share. As a group, equities research analysts predict that Taysha Gene Therapies will post -0.41 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning acquired 1,333,333 shares of the stock in a transaction on Thursday, June 27th. The shares were acquired at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the transaction, the insider now owns 1,333,333 shares in the company, valued at approximately $2,999,999.25. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.70% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

Large investors have recently bought and sold shares of the company. Howard Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies during the 4th quarter valued at $25,000. Victory Capital Management Inc. bought a new position in Taysha Gene Therapies during the fourth quarter worth about $28,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Taysha Gene Therapies in the fourth quarter worth about $31,000. Principal Financial Group Inc. bought a new stake in shares of Taysha Gene Therapies in the second quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $38,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.